Business Wire

UNC Health Care System Selects ARxIUM for Expansion of Shared Services Center

Del

ARxIUM, an industry-leading developer of pharmacy automation, workflow and consulting solutions, today announced the company was selected as vendor of choice by UNC Health Care to further centralize and increase pharmacy operations of its Shared Services Center. The expanded partnership includes the installation of ARxIUM’s pharmacy inventory management software, RxWorks Pro, and high-density inventory storage, FastFind carousels, to better serve pharmacies in the health system’s network.

RxWorks Pro’s integrated, web-based ordering provides UNC Health Care a comprehensive application to manage medication fulfillment of satellite and clinic pharmacy sites. In addition, its business intelligence feature includes customizable dashboards and reporting options that offer better management of medication inventories and real-time response to pharmacy demands. More importantly, the software interoperates with enterprise platforms and other manufacturers’ pharmacy systems and connects with the FastFind carousels to effectively manage medication supplies.

“We are excited by the opportunity to expand our partnership with UNC Health Care and grow its Shared Services Center into one of the most advanced health system pharmacies in the world,” said Dr. Niels Erik Hansen, president and CEO of ARxIUM. “Their innovative, system-wide approach and pharmacy model is the gold standard for other health systems that are looking to centralize and optimize operations. Our multi-phase engagement will result in a highly automated, interoperable Shared Services Center that can effectively onboard and serve pharmacies and clinics throughout the health system.”

ARxIUM’s plan for the UNC Shared Services Center also includes low-density, fixed shelving for higher demand drugs, FastFind carousels for slower moving medications and sortation to manage material flow. FastFind uses a pharmacy’s vertical height to increase the number of items stored in the same footprint by up to 60 percent. The carousel provides barcode scanning, pick-to-light technology and a drug database to enhance patient safety, and has the ability to purchase medications to replenish inventories. The new applications and equipment will complement UNC Health Care’s usage of other ARxIUM systems, including FastPak Elite, an oral solid pouch packaging system, and OptiFill, a high-volume medication fulfillment solution.

“We selected ARxIUM to expand our Shared Services Center because we rely upon their team to provide custom-configured timely solutions,” said Rowell Daniels, system vice president, pharmacy at UNC Health Care System. “Our ongoing partnership has been a collaborative effort that is focused on developing technologies and integrating systems that adapt to our needs. RxWorks, for example, has the ability to handle complex pharmacy situations and improves our cost savings and productivity.”

The UNC Health Care partnership represents the company’s newest approach to servicing its customers. The company consulted with the health system on the future state of its pharmacy operations and helped define the supply delivery system of medications between its hospitals, clinics and Shared Services Center. Additionally, ARxIUM created project specifications and a business case that was technology agnostic, and it recommended pharmacy equipment and automation to achieve patient care and operational objectives. This collaborative, consultative approach is especially important for pharmacies that are considering centralizing or consolidating operations and it serves as a substantial differentiator from competing pharmacy automation providers.

About ARxIUM
Based in Winnipeg, Manitoba and Buffalo Grove, Illinois, ARxIUM is an industry-leading developer of pharmacy automation, workflow and consulting solutions that improve safety, productivity and workflow. The company provides solutions to shared service centers and health system, hospital, long-term care, retail and government pharmacies. ARxIUM is the developer of the only fully automated IV compounding system in the market today, and offers automated packaging, dispensing, vial filling and high volume systems. In addition, the company provides inventory management, scheduling and workflow software, technical consulting, and system implementation assistance, among other services. ARxIUM is also the creator of the Pharmacy 4.0 approach, which seamlessly converges clinical pharmacy, central production and automation advancements into fully automated, interactive data processes. The approach allows pharmacies to better monitor and react in real-time to address patient care and medication delivery demands. For more information, visit www.arxium.com.

About UNC Health Care
UNC Health Care is an integrated health care system comprised of UNC Hospitals and its provider network, UNC Faculty Physicians, UNC Physicians Network, the clinical patient care programs of the UNC School of Medicine and nine other hospitals and hospital systems across the state. Additional hospital entities include UNC Rex Healthcare, Chatham Hospital, Johnston Health, Pardee Hospital, High Point Regional Health, Caldwell Memorial, Nash Health Care, Wayne Memorial, UNC Lenoir Health Care and UNC Rockingham. For more information, visit www.unchealthcare.org.

Contact information

Cookerly Public Relations
Cory Stewart, 404-816-2037
cory@cookerly.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Cytox Expands Collaboration with AIBL to Identify Those Most at Risk to Rapidly Progress to Alzheimer’s24.9.2018 05:00Pressemelding

Cytox, a precision medicine company which today is commercializing polygenic risk scoring (PRS) approaches for assessing genetic risk for developing Alzheimer’s disease (AD) and other neurological diseases, has announced it has expanded its research collaboration with the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) to test new algorithms for identifying the pre-symptomatic and mild cognitively impaired people most at risk to progress to AD. Under the expanded agreement Cytox will assess genetic risk for accelerated development of AD using its current, commercially available, research use only approaches developed to run on the Thermo Fisher Scientific Applied Biosystems™ GeneTitan™ Multi-Channel (MC) instrument platform. AIBL will provide biobank samples together with associated longitudinal data from study research participants clinically diagnosed as cognitively normal, with mild cognitive impairment or with AD. Each subject has confirmed amyloid status

American Airlines Announces Nonstop Philadelphia (PHL) to Orlando Melbourne (MLB)21.9.2018 22:13Pressemelding

Glorious beaches by day and theme park fireworks by night just got more convenient for Philadelphia travelers. American Airlines announced today that it will begin nonstop flights to Orlando Melbourne International Airport (MLB) starting February 16, 2019. The Central Florida airport is conveniently located in the heart of the tourism region and is the closest airport to NASA rocket launches, Port Canaveral’s cruises and what critics call “some of the most beautiful beaches Florida has to offer.” The flights will depart Saturdays from Philadelphia at 8:05 a.m., arriving in Florida at 10:48 a.m. The Embraer 175 jet arrival time syncs perfectly with cruise ship noon early boarding. Melbourne Airport Express offers nonstop shuttle service to the port, and all major rental car companies are onsite. The return flight to PHL departs at 11:24 a.m. and arrives in PHL at 1:55 p.m., with enough time to connect to some of American’s largest international destinations, including recently announced

Amy Palladino Joins BCW as Executive Vice President, Managing Director, Corporate Practice21.9.2018 17:43Pressemelding

BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Amy Palladino has joined the agency as Executive Vice President, Managing Director in the agency’s U.S. Corporate Practice. Based in New York, Palladino will focus on senior client counsel and executive positioning for the agency’s largest corporate clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005507/en/ Amy Palladino Joins BCW (Burson Cohn & Wolfe) “Amy is a talented and highly experienced communications executive with a track record of solving clients’ complex challenges and building business through smart, integrated communications approaches,” said Chris Foster, President, North America, BCW. “Her creativity and judgement will be enormously valuable to our current and prospective clients.” Palladino has more than 20 years of experience advising global clients across numerous industries, including technology, healthcar

Heidelberg Engineering Announces the CE-Marking of ANTERION21.9.2018 16:41Pressemelding

Heidelberg Engineering, the leader in diagnostic imaging known for the internationally-acclaimed SPECTRALIS ® retina and glaucoma platform, announces the CE-marking of ANTERION ® – an innovative platform designed to transform anterior segment diagnostics and workflow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005442/en/ The new Heidelberg Engineering ANTERION® provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. (Graphic: Business Wire) The new ANTERION provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solution that brings together corneal topography and tomography, anterior segment metrics, axial length measurement and IOL calculation to transform the day-to-day routine of busy practices and clinics. Heidelberg Engineering has leveraged its core OCT technolo

Florian Winterstein Becomes New CEO of Jedox21.9.2018 15:46Pressemelding

The supervisory board of Jedox AG, a leading vendor of business intelligence and enterprise planning software, has appointed Florian Winterstein as Chief Executive Officer (CEO) effective October 2, 2018. This nomination will support Jedox’s international growth and a new development phase initiated by its latest fund raising in April 2018 with Iris Capital, eCAPITAL entrepreneurial Partners AG and Wecken & Cie. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005416/en/ Florian Winterstein (Photo: Business Wire) With 25 years of experience in strategy consulting and leadership in software and service organizations, Winterstein brings to the company a valuable combination of expertise in cloud solutions, business development, and value creation for customers and partners. As former Chief Strategy Officer of BravoSolution, he positioned the software-as-a-service company as trendsetting digitalization partner, extending it

Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib21.9.2018 13:30Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. ALUNBRIG is a tyrosine kinase inhibitor (TKI) designed to target and inhibit the ALK mutation in NSCLC. Approximately three to five percent of NSCLC patients globally have the ALK mutation. If the CHMP opinion is affirmed, and the European Commission approves ALUNBRIG, it will become the only ALK inhibitor available in the European Union as a one tablet per day dose that can be taken with or without food. The randomized, global Phase 2 ALTA trial was designed to investigate the efficacy and safety of ALUNBRIG in patients with locally advanced or metastatic ALK+